EUR 7.48
(2.89%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | 127.37 Million EUR | 132.06% |
2022 | 56.57 Million EUR | 8.73% |
2021 | 52.03 Million EUR | 31.63% |
2020 | 39.52 Million EUR | 19.08% |
2019 | 33.19 Million EUR | 593.59% |
2018 | 4.78 Million EUR | 23.26% |
2017 | 3.88 Million EUR | 7.77% |
2016 | 3.6 Million EUR | -14.17% |
2015 | 4.19 Million EUR | -51.4% |
2014 | 8.63 Million EUR | 18.14% |
2013 | 7.31 Million EUR | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 Q2 | 86.78 Million EUR | 0.0% |
2023 Q2 | 39.2 Million EUR | 0.0% |
2023 FY | 131.28 Million EUR | 132.06% |
2023 Q4 | 95.59 Million EUR | 0.0% |
2022 Q2 | 18.58 Million EUR | 0.0% |
2022 Q4 | 37.98 Million EUR | 0.0% |
2022 FY | 56.57 Million EUR | 8.73% |
2021 FY | 52.03 Million EUR | 31.63% |
2021 Q2 | 26.5 Million EUR | 0.0% |
2021 Q4 | 25.56 Million EUR | 0.0% |
2020 Q2 | 16.17 Million EUR | 0.0% |
2020 Q4 | 23.35 Million EUR | 0.0% |
2020 FY | 39.52 Million EUR | 19.08% |
2019 Q2 | 17.16 Million EUR | 0.0% |
2019 FY | 33.19 Million EUR | 593.59% |
2019 Q4 | 16.03 Million EUR | 0.0% |
2018 FY | 4.78 Million EUR | 23.26% |
2018 Q4 | 2.54 Million EUR | 0.0% |
2018 Q2 | 2.23 Million EUR | 0.0% |
2017 FY | 3.88 Million EUR | 7.77% |
2017 Q4 | 2.02 Million EUR | 0.0% |
2017 Q2 | 1.85 Million EUR | 0.0% |
2016 FY | 3.6 Million EUR | -14.17% |
2016 Q2 | 1.8 Million EUR | 0.0% |
2016 Q4 | 1.8 Million EUR | 0.0% |
2015 Q2 | 1.61 Million EUR | 0.0% |
2015 FY | 4.19 Million EUR | -51.4% |
2015 Q4 | 2.58 Million EUR | 0.0% |
2014 Q4 | 2.4 Million EUR | 200100.0% |
2014 FY | 8.63 Million EUR | 18.14% |
2014 Q1 | -151.50 EUR | 0.0% |
2014 Q2 | 303 Thousand EUR | 200100.0% |
2014 Q3 | -1202.50 EUR | -100.4% |
2013 FY | 7.31 Million EUR | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
ABIONYX Pharma SA | 4.17 Million EUR | -2949.462% |
Adocia SA | 15.62 Million EUR | -714.998% |
Aelis Farma SA | 18.81 Million EUR | -576.848% |
Biophytis S.A. | 14.33 Million EUR | -788.69% |
Advicenne S.A. | 8.21 Million EUR | -1450.53% |
genOway Société anonyme | 16.73 Million EUR | -660.986% |
IntegraGen SA | 5.35 Million EUR | -2279.743% |
Medesis Pharma S.A. | 1.56 Million EUR | -8041.268% |
Neovacs S.A. | 10.34 Million EUR | -1131.454% |
NFL Biosciences SA | 4.37 Million EUR | -2811.882% |
Plant Advanced Technologies SA | 2.76 Million EUR | -4506.977% |
Quantum Genomics Société Anonyme | 1.71 Million EUR | -7314.354% |
Sensorion SA | 27.05 Million EUR | -370.827% |
Theranexus Société Anonyme | 3 Million EUR | -4138.82% |
TME Pharma N.V. | 5.49 Million EUR | -2217.191% |
Valbiotis SA | 9.86 Million EUR | -1190.668% |
TheraVet SA | 1.64 Million EUR | -7646.457% |
Valerio Therapeutics Société anonyme | 20.32 Million EUR | -526.85% |
argenx SE | 1.34 Billion EUR | 90.513% |
BioSenic S.A. | 7.58 Million EUR | -1579.757% |
Celyad Oncology SA | 8.49 Million EUR | -1400.306% |
DBV Technologies S.A. | 89.4 Million EUR | -42.47% |
Galapagos NV | 327.98 Million EUR | 61.164% |
Genfit S.A. | 54.8 Million EUR | -132.421% |
GeNeuro SA | 14.35 Million EUR | -787.186% |
Hyloris Pharmaceuticals SA | 17.98 Million EUR | -608.156% |
Innate Pharma S.A. | 64.57 Million EUR | -97.268% |
Inventiva S.A. | 120.18 Million EUR | -5.982% |
MaaT Pharma SA | 21.59 Million EUR | -489.758% |
MedinCell S.A. | 32.92 Million EUR | -286.902% |
Nanobiotix S.A. | 58.92 Million EUR | -116.159% |
Onward Medical N.V. | 20.64 Million EUR | -516.982% |
Oryzon Genomics S.A. | 18.49 Million EUR | -588.627% |
OSE Immunotherapeutics SA | 23.58 Million EUR | -439.98% |
Oxurion NV | 12.21 Million EUR | -942.869% |
Pharming Group N.V. | 204.24 Million EUR | 37.637% |
Poxel S.A. | 28.76 Million EUR | -342.816% |
GenSight Biologics S.A. | 32.66 Million EUR | -290.006% |
Transgene SA | 31.23 Million EUR | -307.851% |
Financière de Tubize SA | 114.38 Thousand EUR | -111253.364% |
UCB SA | 2.94 Billion EUR | 95.669% |
Valneva SE | 134.92 Million EUR | 5.594% |
Vivoryon Therapeutics N.V. | 24.69 Million EUR | -415.859% |